SU533323A3 - Способ усилени биологической активности -окситриптофана - Google Patents

Способ усилени биологической активности -окситриптофана

Info

Publication number: SU533323A3
Authority: SU; USSR - Soviet Union
Prior art keywords: hydroxytryptophan; hydrazine; trioxybenzyl; seryl; biological activity
Prior art date: 1972-06-30

Application number

SU1940152A

Other languages

English (en)

Russian (ru)

Inventor

Хефели Вилли

Original Assignee

Ф.Хоффманн Ля Рош И Ко Аг (Фирма)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1972-06-30

Filing date

1973-06-28

Publication date

1976-10-25

1973-06-28 Application filed by Ф.Хоффманн Ля Рош И Ко Аг (Фирма) filed Critical Ф.Хоффманн Ля Рош И Ко Аг (Фирма)

1976-10-25 Application granted granted Critical

1976-10-25 Publication of SU533323A3 publication Critical patent/SU533323A3/ru

Links

230000004071 biological effect Effects 0.000 title description 4
230000002708 enhancing effect Effects 0.000 title description 2
238000000034 method Methods 0.000 title description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
229960002888 oxitriptan Drugs 0.000 description 12
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 11
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000000203 mixture Substances 0.000 description 6
230000036772 blood pressure Effects 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
229940076279 serotonin Drugs 0.000 description 5
229940000681 5-hydroxytryptophan Drugs 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
-1 D, L-seryl Chemical group 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
229940099112 cornstarch Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000001147 pulmonary artery Anatomy 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
LDCYZAJDBXYCGN-UHFFFAOYSA-N 5-hydroxytryptophan Chemical compound C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
208000027796 Blood pressure disease Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000002535 acidifier Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000010908 decantation Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000010773 plant oil Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002072 seryl group Chemical group 0.000 description 1
239000012748 slip agent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
108010021724 tonin Proteins 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SU1940152A 1972-06-30 1973-06-28 Способ усилени биологической активности -окситриптофана SU533323A3 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH984672		1972-06-30

Publications (1)

Publication Number	Publication Date
SU533323A3 true SU533323A3 (ru)	1976-10-25

Family

ID=4356299

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SU1940152A SU533323A3 (ru)	1972-06-30	1973-06-28	Способ усилени биологической активности -окситриптофана

Country Status (18)

Country	Link
AT (1)	AT338412B (fr)
AU (1)	AU476456B2 (fr)
BE (1)	BE801645A (fr)
CA (1)	CA1015272A (fr)
DD (1)	DD107592A5 (fr)
DE (1)	DE2327636A1 (fr)
ES (1)	ES416383A1 (fr)
FR (1)	FR2190453B1 (fr)
GB (1)	GB1369189A (fr)
HU (1)	HU167292B (fr)
IE (1)	IE37833B1 (fr)
IL (1)	IL42317A (fr)
LU (1)	LU67898A1 (fr)
NL (1)	NL7308435A (fr)
PH (1)	PH9584A (fr)
SE (1)	SE407744B (fr)
SU (1)	SU533323A3 (fr)
ZA (1)	ZA733284B (fr)

1973
- 1973-05-15 ZA ZA733284A patent/ZA733284B/xx unknown
- 1973-05-18 AU AU55897/73A patent/AU476456B2/en not_active Expired
- 1973-05-21 IL IL42317A patent/IL42317A/en unknown
- 1973-05-30 DE DE19732327636 patent/DE2327636A1/de active Pending
- 1973-06-18 NL NL7308435A patent/NL7308435A/xx not_active Application Discontinuation
- 1973-06-22 IE IE1034/72A patent/IE37833B1/xx unknown
- 1973-06-27 FR FR7323456A patent/FR2190453B1/fr not_active Expired
- 1973-06-28 LU LU67898A patent/LU67898A1/xx unknown
- 1973-06-28 CA CA175,140A patent/CA1015272A/en not_active Expired
- 1973-06-28 PH PH14782*UA patent/PH9584A/en unknown
- 1973-06-28 ES ES416383A patent/ES416383A1/es not_active Expired
- 1973-06-28 SU SU1940152A patent/SU533323A3/ru active
- 1973-06-29 HU HUHO1588A patent/HU167292B/hu unknown
- 1973-06-29 SE SE7309254A patent/SE407744B/xx unknown
- 1973-06-29 BE BE132885A patent/BE801645A/fr unknown
- 1973-06-29 GB GB3107173A patent/GB1369189A/en not_active Expired
- 1973-06-29 DD DD171943A patent/DD107592A5/xx unknown
- 1973-06-29 AT AT574273A patent/AT338412B/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
FR2190453A1 (fr)	1974-02-01
AU5589773A (en)	1974-11-21
ES416383A1 (es)	1976-02-16
HU167292B (fr)	1975-09-27
IE37833B1 (en)	1977-10-26
NL7308435A (fr)	1974-01-02
CA1015272A (en)	1977-08-09
ATA574273A (de)	1976-12-15
DD107592A5 (fr)	1974-08-12
GB1369189A (en)	1974-10-02
FR2190453B1 (fr)	1976-04-09
PH9584A (en)	1976-01-19
IL42317A0 (en)	1973-07-30
AT338412B (de)	1977-08-25
BE801645A (fr)	1974-01-02
AU476456B2 (en)	1976-09-23
SE407744B (sv)	1979-04-23
IE37833L (en)	1973-12-30
DE2327636A1 (de)	1974-01-17
ZA733284B (en)	1974-03-27
IL42317A (en)	1976-04-30
LU67898A1 (fr)	1975-04-11

Publication	Publication Date	Title
US2892753A (en)	1959-06-30	Central nervous system stimulant
KR950009094B1 (ko)	1995-08-14	과유지질혈증 및 아테롬성 동맥경화증의 방지 및 치료용 피리독신 유도체를 함유한 제약학적 조성물
US4898729A (en)	1990-02-06	Treatment of hypertension, compounds and compositions for antihypertension and diuresis
RU2160589C1 (ru)	2000-12-20	Средство для снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома и способ снижения алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома с использованием этого средства
JPS6313967B2 (fr)	1988-03-29
US3557292A (en)	1971-01-19	Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine
RU92004569A (ru)	1998-05-10	Фармацевтический препарат антистрессорного, стресспротекторного и ноотропного действия
KR20020060192A (ko)	2002-07-16	Ｎｋ₁ 수용체 길항제와 ｇａｂａ 구조유사체의 상승적배합물
NL192870C (nl)	1998-04-02	Anti-hypertensief oraal farmaceutisch preparaat.
DE3875611T2 (de)	1993-03-11	Pharmazeutische zusammensetzungen.
JPS5938203B2 (ja)	1984-09-14	補酵素ｑを主成分とする脳循環障害治療剤
NO822385L (no)	1983-01-14	Terapeutisk preparat.
US5026706A (en)	1991-06-25	Method for treating dysuria using naftopidil
Dam et al.	1981	Carbamazepine: a clinical biopharmaceutical study
US3896232A (en)	1975-07-22	Substituted benzylidene hydrazines as anti-migraine syndrome agents
RU2084225C1 (ru)	1997-07-20	Гипотензивное средство
RU2725622C1 (ru)	2020-07-03	Фармацевтическая композиция для лечения и/или профилактики заболеваний печени
RU2152221C1 (ru)	2000-07-10	Средство, обладающее гепатопротекторным, холестерино- и сахарорегулирующим действием
US3932652A (en)	1976-01-13	Antidepressant compositions
US3360434A (en)	1967-12-26	Method for reducing blood pressure with phenylalanine derivatives
Borysiewicz et al.	1981	Scombrotoxic atrial flutter
IE71022B1 (en)	1997-01-15	Stabilizer for 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamides containing preparation and stabilizing method therefor
RU2341254C1 (ru)	2008-12-20	Стабильная фармацевтическая композиция, обладающая антигипертензивным действием
US4218466A (en)	1980-08-19	Method of treating gastric and duodenal ulcers
KR970006083B1 (ko)	1997-04-23	위장질환 치료용 의약 조성물